Skip to main content
Premium Trial:

Request an Annual Quote

Sage Licenses CRISPR-Cas9 Technology from Broad Institute

NEW YORK (GenomeWeb) – Sage Labs today announced it has licensed CRISPR-Cas9 genome editing technology from the Broad Institute.

The license provides Sage the ability to use the technology — for which Broad recently was awarded the first US patent covering the CRISPR-Cas9 technology — to engineer cell and animal models for its clients. Sage will also be able to distribute validated CRISPR reagents, it said. The St. Louis-based company previously licensed CRISPR-Cas9 technology from Caribou Biosciences.

Financial and other terms of the deal were not disclosed.

Sage provides gene editing tools, research models, and support services. While the Broad received the first CRISPR-Cas9 patent, the IP landscape surrounding the technology is becoming increasingly murky, and in a statement Sage CEO David Smoller said that it is crucial that the firm's clients "receive the freedom to operate with their research models, and we're committed to obtaining the necessary licenses."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.